Brown Advisory’s Iterum Therapeutics ITRM Stock Holding History

Brown Advisory’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,000	Closed	-$12K	–	1147
2022 Q2	$12K	Hold	4,000	–	–	﹤0.01%	1099
2022 Q1	$21K	Hold	4,000	–	–	﹤0.01%	1105
2021 Q4	$24K	Hold	4,000	–	–	﹤0.01%	1232
2021 Q3	$34K	Buy	+4,000	New	+$49.3K	﹤0.01%	1096

Other funds holding ITRM

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brown Advisory's ITRM Position: Q3 2022 in Review

Brown Advisory sold out of Iterum Therapeutics (ITRM) in Q3 2022, closing a stake of 4,000 shares — an estimated $12K sold.

Brown Advisory first reported a position in ITRM in Q3 2021 and held it in 4 quarters. The position peaked at $34K in Q3 2021. 25 funds tracked by Wall St. Rank hold ITRM as of Q3 2022.

Brown Advisory reported no remaining Iterum Therapeutics position as of Q3 2022 after selling out during the quarter.
Brown Advisory sold 4,000 Iterum Therapeutics shares in Q3 2022, an estimated $12K.
Brown Advisory first reported a position in Iterum Therapeutics in Q3 2021 and held it in 4 quarters.
Brown Advisory's Iterum Therapeutics position peaked at $34K in Q3 2021.
25 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2022.

Based on Brown Advisory's 13F filing for Q3 2022, filed 14 Nov 2022.